Pregabalin Capsule
Product Images NDC 71335-3118

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-3118). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713353118)

Pregabalin Capsules 150 mg oral capsules label showing NDC 71335-3118-1, repackaged by Bryant Ranch Prepack and manufactured by ScieGen Pharmaceuticals. The label includes storage instructions, prescription use indication, package size of 30 capsules, and QR codes for additional information.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at different dosages (200 mg three times a day, 100 mg three times a day, 25 mg three times a day) and placebo. The graph shows separate lines for each dose and placebo, with improvement percentages along the x-axis and percent of patients improved on the y-axis.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day to placebo. The graph shows two curves representing the treatment and placebo groups across a range of pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph depicting percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares four groups: Pregabalin 300 mg twice daily, Pregabalin 150 mg twice daily, Pregabalin 75 mg twice daily, and placebo, showing trends of patient improvement across different pain improvement levels.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows the relationship between pain improvement percentages and patient response rates across the three groups.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing the percent of patients improved on the y-axis against percent improvement in pain from baseline on the x-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, with separate lines for each treatment group.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar graph comparing responder rates (%) in two studies, Study E1 and Study E3, for different doses of an oral drug versus placebo. The x-axis shows dosage groups and the y-axis shows responder rate percentages. Statistically significant differences versus placebo are indicated.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph showing seizure reduction as median percent change from baseline versus dose (mg/day) for Pregabalin. The plot compares results from four studies (E1 BD, E2 TID, E3 BD, E3 TID) with dose levels from 0 to 600 mg/day. Significant p-values are indicated on the graph showing statistical reductions in seizure frequency at various doses compared to placebo.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline comparing Pregabalin at 800 mg, 450 mg, 300 mg daily doses and placebo. The y-axis represents percent of patients improved from 0 to 100%, and the x-axis shows percent improvement in pain from baseline ranging from greater than 0 to 100%.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph showing the estimated percentage of subjects without LTR over 180 days comparing Pregabalin with Placebo. The y-axis represents the percentage of subjects without LTR, and the x-axis shows days from 0 to 180. Two lines depict the outcomes: a solid line for Pregabalin and a dashed line for Placebo, with Pregabalin maintaining higher percentages throughout the period.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph depicting the percent of subjects improved from baseline to Week 12 BOCF, comparing Pregabalin and Placebo. The x-axis shows percent improvement from 0 to 100, and the y-axis shows the percentage of subjects improved from 0 to 100%. The solid line represents Pregabalin and the dotted line represents Placebo, illustrating greater improvement trend with Pregabalin over Placebo.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved from baseline to week 16 BOCF between Pregabalin and placebo groups. The x-axis shows percent improved, ranging from greater than 0 to 100 percent, and the y-axis shows the percent of subjects improved, decreasing from 100 to 0 percent. Two lines represent Pregabalin (solid line) and placebo (dashed line), with the Pregabalin group showing consistently higher percentages of subjects improved versus placebo.*

FDA Label Image

Figure 13 (Pregabalin Fig13)

A bar graph showing responder rates (%) for Pregabalin at doses of 2.5 mg/kg/day and 10 mg/kg/day compared to placebo. The y-axis represents responder rate percentages, while the x-axis shows placebo and two dosage groups with sample sizes of 93, 103, and 96, respectively. The 10 mg/kg/day group has the highest responder rate.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A text panel showing the formula for calculating creatinine clearance (CLcr), which includes age, weight, serum creatinine, and a factor adjustment for female patients. The formula is presented with variables and constants for clinical calculation.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure diagram of Pregabalin, showing its molecular formula with functional groups including a carboxyl (CO2H) and an amino (NH2) group attached to a branched carbon backbone.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.